| 2016-10-05 16:12:24|
AMGN 16:12 10/05 10/05/16
Amgen to present new data on IMLYGIC, Vectibix at ESMO
Amgen announced that new data on IMLYGIC in combination with an immune checkpoint inhibitor and results from retrospective analyses on Vectibix will be presented at the European Society for Medical Oncology 2016 Congress, Oct. 7-11, 2016, in Copenhagen. IMLYGIC presentations include interim results from a Phase 2 trial evaluating IMLYGIC in combination with ipilimumab versus ipilimumab alone in patients with unresected stage IIIB-IV melanoma. Vectibix abstracts include retrospective analyses of the first-line Phase 3 PRIME and PEAK studies, evaluating the association between tumor site of origin and treatment efficacy in patients with RAS wild-type metastatic colorectal cancer.